HIV

The Pharmacy Times® human immunodeficiency virus (HIV) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?

Patients Receiving Nucleoside Reverse Transcriptase Inhibitors at Lower Risk of COVID-19

During this study, no patient receiving TDF and FTC was admitted to intensive care or died.

FDA Approves Rilpivirine, Cabotegravir as the First Long-Acting Regimen for HIV Treatment

The FDA has approved cabenuva, which consists of rilpivirine and cabotegravir, for treating HIV-1 infection in adults. This therapy is the first once-monthly, long-acting injectable to be approved for the treatment of HIV.

Investigational Injectable Cabotegravir Is Superior to Oral Standard of Care for Women

The study results showed that cabotegravir was 89% more effective than daily oral FTC/TDF for preexposure prophylaxis (PrEP).

Attitudes Toward Long-acting Injectable HIV Therapy May Vary Among Women

A recent study sought to investigate the attitudes of women with a history of injection—both medical and substance use—toward long-acting injectable HIV therapies.

Study: Formula Predicts Ideal Dose of Stem Cells to Cure HIV

The right balance of stem cell dose, cell type, and timing of antiretroviral therapy (ART) could potentially lead to a spontaneous cure of HIV, according to the study authors.

Low Immunity Linked to Poor Outcomes in Patients with HIV, COVID-19

As patients with HIV are living longer, they are also being diagnosed with chronic conditions that have become increasingly common in recent decades, putting them at higher risk of COVID-19 hospitalization and death.

The Importance of Conducting PrEP Counseling With a Sex Positive Approach

At the virtual 2020 ASHP Midyear Clinical Meeting and Exhibition, Elyse Tung, PharmD, BCACP, discussed key counseling points for pharmacists to address with patients when prescribing and managing PrEP.

Rukobia From ViiV Healthcare

The FDA has approved Rukobia (fostemsavir) for the treatement of human immunodeficiency virus 1 (HIV-1) infection.

Non-oral PrEP Options Are Being Investigated to Improve Patient Adherence

Additional non-oral options could provide more manageable forms of PrEP treatment for patients, potentially increasing global uptake of PrEP in the future.

Investigational Injectable Cabotegravir Superior to Oral Standard of Care for Female HIV Prevention

Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).

Investigational Injectable Cabotegravir Superior to Oral Standard of Care for HIV Prevention in Women

Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).

Pharmacists Play a Critical Role in Managing HIV Care Changes During COVID-19

The US Department of Health & Human Services released guidance at the beginning of the pandemic clarifying guidelines regarding best practices in HIV care.

Medication adherence plays a vital role in the success, or failure, of patients with HIV/AIDS. This Pharmacy Times® specialty page serves as a hub for all clinical news that pharmacists need to know about HIV treatment and possible prevention. The coverage includes breaking news coverage of approvals from the US Food and Drug Administration, key takeaways from the latest novel therapies in clinical trials, and notifications of updates to clinical guidelines for the conditions. Additionally, this page provides suggestions for ways that pharmacists can collaborate with physicians to help overall continued care.